Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7039338rdf:typepubmed:Citationlld:pubmed
pubmed-article:7039338lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0017687lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0021641lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0205054lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0020456lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:7039338lifeskim:mentionsumls-concept:C0205374lld:lifeskim
pubmed-article:7039338pubmed:issue2lld:pubmed
pubmed-article:7039338pubmed:dateCreated1982-5-21lld:pubmed
pubmed-article:7039338pubmed:abstractTextWe infused glucagon into normal humans while preventing changes in plasma glucose and insulin. Insulin (0.45 mU . min-1 . kg-1) were infused for 90 min, while euglycemia was maintained by a variable glucose infusion. Subsequently, glucagon (6 ng . min-1 . kg-1) was added, and changes in plasma glucose were avoided by appropriately reducing the glucose infusion. With insulin alone, glucose production (GP) fell to zero. When hyperglucagonemia (530 +/- 32 pg/ml) was superimposed, GP rose promptly and then slowly declined. However, between 180 and 240 min, GP remained elevated (1.72 +/- 0.30 mg . min-1 . kg-1) as compared to an insulin control study (0.03 +/- 0.20, P less than 0.025). When hyperglycemia (+25 mg/100 ml) was induced between 180 and 240 min, glucagon-stimulated GP was completely suppressed. To determine whether this effect was mediated by hyperglycemia per se or glucose-induced hyperinsulinemia, between 180 and 240 min we increased either a) the insulin infusion (by 0.25 mU . min-1 . kg-1) while maintaining euglycemia or b) plasma glucose (+25 mg/100 ml) while blocking insulin release with somatostatin. When the insulin was increased, GP declined by 68 +/- 13% (P less than 0.02). When plasma glucose alone was raised, GP fell from 1.44 +/- 0.09 to 0.07 +/- 0.16 mg . min-1 . kg-1 (less than 0.002). In conclusion, the hepatic response to sustained hyperglucagonemia is more persistent if changes in plasma glucose are prevented, and its transient nature is in part explained by a feedback adjustment to glucagon-induced hyperglycemia and hyperinsulinemia.lld:pubmed
pubmed-article:7039338pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:languageenglld:pubmed
pubmed-article:7039338pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:citationSubsetIMlld:pubmed
pubmed-article:7039338pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7039338pubmed:statusMEDLINElld:pubmed
pubmed-article:7039338pubmed:monthFeblld:pubmed
pubmed-article:7039338pubmed:issn0002-9513lld:pubmed
pubmed-article:7039338pubmed:authorpubmed-author:FerranniniEElld:pubmed
pubmed-article:7039338pubmed:authorpubmed-author:DeFronzoR ARAlld:pubmed
pubmed-article:7039338pubmed:authorpubmed-author:SherwinR SRSlld:pubmed
pubmed-article:7039338pubmed:issnTypePrintlld:pubmed
pubmed-article:7039338pubmed:volume242lld:pubmed
pubmed-article:7039338pubmed:ownerNLMlld:pubmed
pubmed-article:7039338pubmed:authorsCompleteYlld:pubmed
pubmed-article:7039338pubmed:paginationE73-81lld:pubmed
pubmed-article:7039338pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:meshHeadingpubmed-meshheading:7039338-...lld:pubmed
pubmed-article:7039338pubmed:year1982lld:pubmed
pubmed-article:7039338pubmed:articleTitleTransient hepatic response to glucagon in man: role of insulin and hyperglycemia.lld:pubmed
pubmed-article:7039338pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7039338pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7039338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7039338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7039338lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7039338lld:pubmed